Nov 13, 2025 03:55
ANNX - Annexon, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 4.18 0.09 (2.15%) | 0.0 (-0.01%) | 0.01 (0.23%) | 0.0 (0.0%) | 0.12 (2.87%) | -0.02 (-0.47%) | 0.12 (2.76%) | 0.02 (0.45%) |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Earnings & Ratios
- Basic EPS:
- -0.34
- Diluted EPS:
- -0.34
- Basic P/E:
- -12.5588
- Diluted P/E:
- -12.5588
- RSI(14) 1m:
- 56.52
- VWAP:
- 4.27
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|
Related News
Jul 24, 2025 11:00
Jun 03, 2025 17:00
May 09, 2025 21:00
Apr 03, 2025 22:18
Jan 07, 2025 13:00
Jul 11, 2024 22:10
Jun 28, 2024 13:40
Jun 27, 2024 13:55
Jun 25, 2024 21:00